A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China – CNBC
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China CNBC Lung Cancer Patients on Drug From China’s Akeso Lived Longer Bloomberg.com ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% Fierce Pharma Akeso and Summit’s ivonescimab extends survival in squamous cell …